Which of the branched-chain amino acids increases cerebral blood flow in hepatic encephalopathy? A double-blind randomized trial

Autor(es):Mostrar menos -

Romeiro, Fernando Gomes ^[1] ; Ietsugu, Marjorie do Val ^[1] ; Franzoni, Leticia de Campos ^[1] ; Augusti, Lais ^[1] ; Alvarez, Matheus ^[2] ; Amaral Santos, Livia Alves ^[1] ; Lima, Talles Bazei ^[1] ; Koga, Katia Hiromoto ^[3] ; Moriguchi, Sonia Marta ^[3] ; Caramori, Carlos Antonio ^[1] ; Silva, Giovanni Fari ^[1] ; Gomes Garcia Betting, Luiz Eduardo ^[4]

Afiliação do(s) autor(es)

^[1] UNESP Univ Estadual Paulista, Botucatu Med Sch, Dept Internal Med, Av Prof Mario Rubens Guimaraes Montenegro S-N, BR-18618687 Botucatu, SP - Brazil

^[2] UNESP Univ Estadual Paulista, Dept Phys & Biophys, Botucatu Biosci Inst, Rua Prof Dr Antonio Celso Wagner Zanin S-N, BR-18618689 Botucatu, SP - Brazil

^[3] UNESP Univ Estadual Paulista, Botucatu Med Sch, Dept Trop Dis & Imaging Diag, Av Prof Mario Rubens Guimaraes Montenegro S-N, BR-18618687 Botucatu, SP - Brazil

^[4] UNESP Univ Estadual Paulista, Botucatu Med Sch, Dept Neurol Psychol & Psychiat, Av Prof Mario Rubens Guimaraes Montenegro S-N, BR-18618687 Botucatu, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: NEUROIMAGE-CLINICAL; v. 19, p. 302-310, 2018.
• Citações Web of Science: 1

Resumo

Branched-chain amino acids increase the brain perfusion of patients with hepatic encephalopathy (HE), but the amino acid and the mechanisms involved are still unknown. This study compared brain perfusion and clinical improvement during leucine or isoleucine supplementation. After randomization, 27 subjects with cirrhosis and HE received leucine or isoleucine supplements for one year. Brain single Photon Emission Computed Tomography (SPECT) and dynamic brain scintigraphy (DBS) were performed pretreatment and at 1, 8 and 12 months of supplementation. Brain perfusion was increased only in the isoleucine group at 8 months of treatment by both SPECT and DBS (p < 0.001 and p = 0.05, respectively) and by SPECT at the 12th month (p < 0.05). This was associated with hepatic encephalopathy improvement at 8 and 12 months (p = 0.008 and 0.004, respectively), which was not observed in the leucine group (p = 0.313 and 0.055, respectively). Isoleucine supplementation achieved a better impact on brain perfusion restoration in HE. (AU)

• Processo FAPESP: 14/22572-9 - Resposta ao tratamento da osteoporose e da osteopenia em portadores de cirrose hepática
• Beneficiário: Lívia Alves Amaral Santos
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 16/07117-9 - Risedronato no tratamento de osteoporose em portadores de cirrose com varizes esofágicas: avaliação sobre segurança e eficácia na recuperação da massa óssea
• Beneficiário: Fernando Gomes Romeiro
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/15121-8 - Ensaio clínico prospectivo, randomizado, duplo-cego e controlado sobre os efeitos da leucina versus isoleucina no tratamento da encefalopatia hepática de acordo com o estado nutricional de portadores de cirrose
• Beneficiário: Lais Augusti
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 13/11761-2 - Estudo clínico randomizado, duplo-cego e controlado sobre a ação de aminoácidos de cadeia ramificada sobre o pH sanguíneo e o fluxo cerebral de portadores de cirrose com encefalopatia hepática
• Beneficiário: Fernando Gomes Romeiro
• Modalidade de apoio: Auxílio à Pesquisa - Regular